Home banner
Divider
A-Z Index

Quick way to the find the information that you need...

More button
Register with FRAME

Although you do not need to register, any information you provide will be confidential and used only by FRAME to improve the website

Register button
Account Login
Forgot password?

ATLA - ISI
The Journal

 

Alternatives to Laboratory Animals - ATLA

Download latest issue button Download back issues button Subscribe to ATLA
Contact Us

Tel icon

Tel: +44 (0)115 9584740


Tel icon

Fax: +44 (0)115 9503570

Make an Enquiry

Omics, Biomarkers and New Technologies

 

Traditional in vivo and in vitro assays have relied on measuring a few parameters at best, such as changes in the levels of a particular chemical, signalling mediator or hormone in the body.

 

This approach provides a mere snapshot of the possible effects of a substance within the body, such that clinical signs in animal tests or effects seen in cell-based assays do not reliably translate to monitoring the effects of a substance during human studies.

 

This has been attributed to the high rate of drugs failing to reach clinical use or they are subsquently withdrawn because of adverse side effects. The US Food and Drug Administration (FDA) is looking at how new technologies based on using biomarkers can help to reduce the incidence of these problems.

 

Biomarkers may be biochemical or metabolic, related to  genes and their expression patterns under different circumstances or in different individuals. These biomarkers are discovered by monitoring a broad range of changes in gene expression, protein levels or metabolites and are encompassed in the fields of genomics, proteomics and metabonomics, respectively.